BD Statement On FTC Clearance Of Bard Acquisition
FRANKLIN LAKES, N.J., Dec. 22, 2017 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, issued the following statement regarding today’s clearance by the U.S. Federal Trade Commission (FTC) for BD to acquire C. R. Bard (NYSE: BCR), contingent on the divestitures of BD’s soft tissue core needle biopsy product... Read more